Trials / Completed
CompletedNCT05616728
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP-235 | capsule |
| DRUG | Placebo | capsule |
Timeline
- Start date
- 2022-11-10
- Primary completion
- 2023-02-08
- Completion
- 2023-06-29
- First posted
- 2022-11-15
- Last updated
- 2024-08-19
- Results posted
- 2024-08-19
Locations
23 sites across 2 countries: United States, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05616728. Inclusion in this directory is not an endorsement.